How common is pulmonary fibrosis? 

Pulmonary fibrosis is considered a relatively rare condition, but its impact on the UK healthcare system is significant and growing. While it is not as widely discussed in the media as other respiratory conditions like asthma or chronic obstructive pulmonary disease, thousands of people are diagnosed with lung scarring every year. The frequency of the condition is closely linked to specific demographic factors, particularly age and gender, and recent data suggests that the number of people living with these conditions in the UK is higher than previously estimated. Understanding the prevalence of this disease is vital for ensuring that resources and specialist services are properly allocated to support those affected. 

What We’ll Discuss in This Article 

• The total number of people currently living with pulmonary fibrosis in the UK. 

• Annual diagnosis rates for idiopathic pulmonary fibrosis (IPF). 

• How age and gender influence the likelihood of developing the condition. 

• The impact of the disease on UK mortality and hospital services. 

• Geographical trends and common comorbidities seen in UK patients. 

Total prevalence in the United Kingdom 

Pulmonary fibrosis affects a significant number of people across the UK, though exact figures can vary depending on whether all types of lung scarring are included in the count. Approximately 70,000 people in the UK are currently living with some form of pulmonary fibrosis, which includes scarring caused by environmental factors, autoimmune diseases, and unknown triggers. Of these cases, idiopathic pulmonary fibrosis (IPF) is the most frequently diagnosed specific type. Current estimates suggest that roughly 32,500 people in the UK have a confirmed diagnosis of IPF, a figure that has risen in recent years. This increase is thought to be due to a combination of improved diagnostic tools, such as high-resolution CT scans, and a generally ageing population in the UK. 

Annual diagnosis rates and incidence 

The number of new cases identified each year provides a clear picture of the ongoing burden of the condition on the healthcare system. Around 6,000 new cases of idiopathic pulmonary fibrosis are diagnosed annually in the UK, which equates to roughly 15 to 20 people being told they have the condition every single day. Some recent research suggests this number may actually be as high as 8,000 to 9,000 new cases per year when broader diagnostic criteria are applied by specialist teams. This steady influx of new patients highlights the growing need for efficient referral pathways between primary care and secondary specialist lung centres. Early detection is particularly important as it allows for the earlier introduction of treatments that can slow the progression of the disease. 

Demographic trends: Age and gender 

Pulmonary fibrosis is significantly more common in older adults and shows a clear disparity between men and women. The condition is rarely seen in people under the age of 50, with approximately 85% of all diagnoses occurring in those aged 70 or older. Men are also disproportionately affected, accounting for approximately 75% to 80% of all cases in the UK. While the reasons for this gender gap are not fully understood, it is thought to be a combination of historical occupational exposures, such as working in heavy industry or construction, and potential biological differences. The average age at which a person is first seen in a hospital for these symptoms is around 74 years old. 

Demographic Group	Proportion of Total IPF Cases
People aged 70 and over	Approximately 85%
Men	Approximately 75-80%
Women	Approximately 20-25%

Geographical distribution within the UK 

There is some evidence to suggest that the prevalence of pulmonary fibrosis is not uniform across the United Kingdom. Data from various registries indicates that certain regions, such as Northern Ireland, North West England, Scotland, and Wales, have slightly higher rates of the condition compared to other areas like London. These geographical variations may be linked to the historical concentration of industries where workers were exposed to harmful dusts and fibres. However, researchers continue to study these patterns to determine if other factors, such as environmental air quality or regional genetic clusters, also play a role in the distribution of the disease. 

Impact on UK healthcare and mortality 

Despite being classified as a less common disease, the impact of pulmonary fibrosis on hospital services and mortality in the UK is substantial. It is estimated that one in every 100 deaths in the UK is now caused by idiopathic pulmonary fibrosis, which is a higher mortality rate than some better-known conditions like leukaemia or certain types of skin cancer. This translates to nearly 5,000 to 6,000 deaths annually. Furthermore, the condition accounts for approximately 9,000 hospital admissions and over 80,000 hospital bed days each year. This places a consistent and significant demand on respiratory wards and specialist lung multidisciplinary teams. 

Diagnostic delays and misdiagnosis 

Because the symptoms of pulmonary fibrosis can be similar to other more common heart and lung conditions, many patients experience a delay in receiving an accurate diagnosis. It is estimated that around 30% of patients have to wait six months or more for a referral to a specialist after they first visit their GP with symptoms. In some cases, patients are initially misdiagnosed with conditions like asthma or heart failure. Improving the awareness of “velcro-like” crackles in the lungs during a physical examination is one way the NHS is working to speed up the identification of these patients. Reducing the time between the onset of symptoms and the start of specialist treatment remains a priority for UK respiratory health policy. 

Conclusion 

Pulmonary fibrosis is a more common condition in the UK than many realise, with tens of thousands of people currently managing the disease. Its prevalence is strongly weighted toward the older male population, and the number of annual diagnoses continues to climb as our population ages and diagnostic precision improves. Recognising these trends is essential for ensuring that the NHS can provide the necessary specialist support, such as pulmonary rehabilitation and antifibrotic medications, to those who need them. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides a factual overview of the prevalence and incidence of pulmonary fibrosis in the United Kingdom. All statistics and demographic data are sourced from current NHS and NICE reports to ensure the highest level of accuracy for the general public. The content has been compiled by a medical content team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician, to ensure clinical safety and alignment with UK health standards.